Chemomab Therapeutics (CMMB) Non Operating Income (2018 - 2019)
Chemomab Therapeutics posted quarterly Non Operating Income of $12.5 million for Q3 2019, up 20656.67% year-on-year from N/an in Q3 2018, and up 549.28% on a QoQ basis from -$2.8 million in Q2 2019.
Chemomab Therapeutics (CMMB) has 2 years of Non Operating Income data on file, last reported at $12.5 million in Q3 2019.
- For the quarter ending Q3 2019, Non Operating Income rose 20656.67% year-over-year to $12.5 million; the trailing twelve-month figure through Sep 2019 stood at $22.1 million (changed N/A YoY), and the FY2025 full-year result was $572000.0, down 27.96% from the prior year.
- Non Operating Income for Q3 2019 stood at $12.5 million, up from -$2.8 million in the prior quarter.
- Across five years, Non Operating Income topped out at $12.9 million in Q1 2019 and bottomed at -$2.8 million in Q2 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 12.45 Mn |
| Jun 30, 2019 | -2.77 Mn |
| Mar 31, 2019 | 12.87 Mn |
| Dec 31, 2018 | -480,000.00 |
| Sep 30, 2018 | 60,000.00 |
| Jun 30, 2018 | 806,000.00 |
| Mar 31, 2018 | 76,000.00 |